Desai AV, Naranjo A, LaBarre B, Chen L, Goldsmith KC, Granger MP, States L, Green SG, Trunzo M, Fitzgerald W, DuBois SG, Bagatell R, Park JR, Marachelian A. A pilot study of chemoimmunotherapy in the postconsolidation setting for high-risk neuroblastoma (ANBL19P1): A report from the Children’s Oncology Group. Cancer. 2026 Jan 15;132(2):e70165. doi: 10.1002/cncr.70165. PMID: 41527287; PMCID: PMC12796553.
Study ID Citation
Abstract
Survival for patients with high‐risk neuroblastoma remains poor despite current‐era multimodality treatment that includes postconsolidation GD2‐directed immunotherapy. Given the promising responses in patients who receive dinutuximab‐based chemoimmunotherapy in the relapsed setting, the Children’s Oncology Group ANBL19P1 study evaluated the feasibility of administering irinotecan, temozolomide, dinutuximab, and sargramostim after frontline consolidation with tandem autologous stem cell transplantation (ASCT).